

thermo scientific **applied** biosystems

invitrogen

gibco

Thermo Fisher SCIENTIFIC

gibco

THE POWER OF BIOLOGICS

Biologics are pharmaceutical drugs derived from or manufactured in living systems. These innovative therapies have a profound impact on treating serious disease and improving the lives of patients worldwide.



A GIBCO™ CELL THERAPY SYSTEMS (CTS) MINI-DOCUMENTARY SERIES

View our series of videos highlighting real world perspective on opportunities and challenges of developing cell-based therapies.

Find out more

CELL-BASED IMMUNOTHERAPY SOLUTIONS

Gibco™ Cell Therapy Systems (CTS™) products offer solutions to support all aspects of your cell therapy development—from bench to clinic and beyond. Here you can learn about our CTS products for immunotherapy or request more information from our experienced team.

Find out more



RECOMBINANT PROTEIN EXPRESSION FOR DEVELOPMENT

OF BIOLOGICS SUCH AS ANTIBODY-BASED DRUGS

Watch exciting webinars on advanced technologies to develop biologics that modulate the immune system to treat serious disease.



Optimisation of UCB's Transient Expression Platforms

To meet the challenge of developing antibody therapeutics, UCB utilises several different transient platforms. Through continuous optmisation, streamlining, and automation of component parts, the UCB panel of platforms (utilising both HEK293 and CHO host cells)

has the capability to produce microgram to gram quantities of panels of purified antibodies and antibody fragments in as little time as 4 weeks from receipt of plasmid DNA.

Christina Gordon Scientist, Protein Services UCB Pharma

Find out more



Stablisation of Native & Functional Membrane Proteins for Drug Discovery

CALIXAR has developed an innovative approach to isolate and stabilise therapeutic membrane protein targets such as GPCRs, ion channels, and transporters. They partnered with Thermo Fisher Scientific

to help tackle the production and characterisation of these very promising and druggable targets to provide a new hope for the development of more accurate drug discovery.


Anass Jawhari Chief Scientific Officer CALIXAR

Find out more

EVERYDAY HERO Ameet Chimote, PhD

Department of Internal Medicine, Division of Nephrology, University of Cincinnati

The challenge: I have been working as a postdoctoral research associate in Dr. Laura Conforti's laboratory (Department of Internal





The solution: Try, try, and try, until you succeed! Under the guidance of my mentor, I "troubleshooted" protocols for isolating TILs based on published procedures in literature and consulted with technical support from companies until I could successfully isolate fully functional T cells from surgically resected head and neck tumours without using any enzymatic dissociation. The cell number I would isolate would vary from patient to patient; but for all of the samples the cell number of the infiltrated lymphocytes was much lower than what I expected. I learned to work with that small cell number and I was able to measure Ca²⁺ fluxes in these cells by flow cytometry and also phenotype them. To complete the "story", I did immunofluorescence staining for ion channel expression and functional markers in sections from these tumours.

Next steps: This was my first foray in the realm of "Translational Research" and I enjoyed the experience very much. Currently there is a lot of interest in studying ion channels in cancer T cells as potential targets for cancer immunotherapy. I want to build up on my experience and technical expertise gained from this project and continue to investigate ion channels in cancer T cells and decipher whether any "defects" in these ion channels can lead to the lack of immune response in cancers.

Learn more